Home
Dashboard
Bookmarks
Portfolios
ExplorerFunds
Equities
Library
Insights
Pinindices
MobileApp Store
Android

Health Care

Next 60 MidCap Biotech FirmsWith market capitalizations between $2bn and $10bn, the performance of the midcap biotech selection has gained momentum
Next 60 MidCap Biotech Firms
  • 118.3%
  • 61
Cell Therapies - Gene EditingInvesting in clinical trial firms, a high stakes bet on breakthrough research
Cell Therapies - Gene Editing
  • 47.0%
  • 19
Global Health Care ETFsDedicated funds with distinct performance / volatility profiles and investment options
Global Health Care ETFs
  • 38.6%
  • 16
Chronic Diseases Confronting diabetes, and many other critical public health problems
Chronic Diseases
  • 4.3%
  • 15
  • 4
Pharma GenericsNew opportunities or an uncertain future ?
Pharma Generics
  • 2.8%
  • 8
  • 1
Health Care Devices & Services ETFsEvaluating dedicated health care funds in aging societies
Health Care Devices & Services ETFs
  • 5.2%
  • 4
HeathcareLarge cap equities controlled for volatility
Heathcare
  • 31.4%
  • 50
Pharmaceuticals MajorsDistinctive strenghts to meet industry challenges
Pharmaceuticals Majors
  • 24.8%
  • 25
  • 5
Sector rotation - Tech industries lose momentumPowerful Pininvest features for analysis of major potential market shifts between sectors and industries
Sector rotation - Tech industries lose momentum
  • -3.6%
  • 6
Biotechnology - Top 100 by Market CapTargeted access to a large selection of biotechnology and pharmaceutical stocks (large-, mid- and small-cap)
Biotechnology - Top 100 by Market Cap
  • 102.4%
  • 100
US NASDAQ 100 ETFsA selection of ETFs seeking to track NASDAQ indices and factors, with a range of filters and of option overlays
US NASDAQ 100 ETFs
  • 25.8%
  • 10
China Biotech - Rising Stars ?Concentrating minds on breakthrough medication - Chinese biotech with a mission
China Biotech - Rising Stars ?
  • 21.8%
  • 11
  • 2
Cancer, Rare Diseases & Cell TherapiesResearch Breakthrough and Pricing Challenges
Cancer, Rare Diseases & Cell Therapies
  • 54.4%
  • 26
  • 2
Swiss Companies - Mid Cap U.S. listingsWith market capitalizations of $2bn to $10bn, MidCap firms, some unfamiliar, with potential investment opportunities
Swiss Companies - Mid Cap U.S. listings
  • 12.9%
  • 34
Biotechnology - Genetic Revolutions Small- and Mid-Cap biotech firms at the forefront of DNA manipulations and gene therapies
Biotechnology - Genetic Revolutions
  • 64.2%
  • 42
Diagnostics Revolutions A focus on advanced medical equipment for in-vitro diagnostics in laboratories and in research
Diagnostics Revolutions
  • 15.9%
  • 23
Medical Advancement, Health and Wellbeing ETFsTaking a long view on transformative trends in healthcare and wellbeing
Medical Advancement, Health and Wellbeing ETFs
  • 40.4%
  • 7
Cannabis - focused ETFsWith a focus on US-based cannabis operators, some ETF highflyers signal the potential of the domestic market and major regulatory uncertainty
Cannabis - focused ETFs
  • 60.2%
  • 7
China Healthcare Logistics - Shock WavesTightly integrated medical ecosystems are upending healthcare logistics in China and around the world
China Healthcare Logistics - Shock Waves
  • 0.4%
  • 10
  • 1
Technology - ARK Innovation, prophet or poster childThe technology fund has been frontrunning market trends on the way up and is riding high, once again
Technology - ARK Innovation, prophet or poster child
  • 24.7%
  • 20
Vaccines markets are collaborative and competitiveWith just 4 major pharmaceutical companies in the lead and 2 powerful mRNA newcomers
Vaccines markets are collaborative and competitive
  • 28.6%
  • 12
  • 5
Biotechnology Breakthroughs ETFsDiversified selections or focused investment models in Biotech R&D
Biotechnology Breakthroughs ETFs
  • 62.0%
  • 10
China Healthcare - Towering domestic challengesAn ecosystem of thousands of Chinese pharmaceutical manufacturers supporting domestic needs and global exports
China Healthcare - Towering domestic challenges
  • -6.5%
  • 8
  • 1
Biotech Movers - a January '23 SurpriseReversal of the negative 2022 trend of biotech firms has been notable - the industry remains volatile but investments could be rewarding
Biotech Movers - a January '23 Surprise
  • 37.1%
  • 17
Healthcare Innovation ETFsDeeply transformative healthcare expectations or ever hopeful promises of basic research advance
Healthcare Innovation ETFs
  • 37.2%
  • 9
Next 60 Small-Cap BiotechSelection of small market cap biotech firms, below $2 billion
Next 60 Small-Cap Biotech
  • 83.4%
  • 60
Cannabis meanderingsMarijuana legalization will probably be staged, one step at a time
Cannabis meanderings
  • 47.0%
  • 20
  • 4
Healthcare - Collaboration in CRISPR ExpertiseA focus on collaborations between giant healthcare companies and clinical trial and research firms - signaling high-value potential (and high-stake bets)
Healthcare - Collaboration in CRISPR Expertise
  • 41.5%
  • 8
Medical Robotics for SurgeryA fast evolving market, technological advance and new potential entrants
Medical Robotics for Surgery
  • -1.6%
  • 9
  • 8
Germany - Market Cap $20bn to $50bnWith a show of resilience, selective exposure to China -a bet on a resurgent German domestic market
Germany - Market Cap $20bn to $50bn
  • -0.6%
  • 17
30 Biotech LargeCap Firms The biotech firms, with market capitalization exceeding $10 billion, are strong contributors to the industry's performance - Momentum is indicative of the sector's resilience
30 Biotech LargeCap Firms
  • 62.5%
  • 30